Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.415
-0.135 (-8.71%)
Mar 31, 2025, 1:25 PM EDT - Market open
Allogene Therapeutics Employees
As of December 31, 2024, Allogene Therapeutics had 229 total employees, including 226 full-time and 3 part-time employees. The number of employees decreased by 4 or -1.72% compared to the previous year.
Employees
229
Change (1Y)
-4
Growth (1Y)
-1.72%
Revenue / Employee
$96
Profits / Employee
-$1,124,847
Market Cap
307.43M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALLO News
- 17 days ago - Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - GlobeNewsWire
- 4 weeks ago - Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities - Seeking Alpha
- 4 weeks ago - Allogene Therapeutics Announces Participation in March Investor Conference - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics: Disrupting CAR-T With A Scalable Model - Seeking Alpha
- 6 weeks ago - Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology - GlobeNewsWire